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Breast cancer is the most frequently diagnosed 
cancer and the leading cause of mortality in females 
worldwide. Despite the great improvement in survival 
rates the last two decades, relapsed disease with metastasis 
still remains the most poorly understood aspect of cancer 
pathogenesis [1]. Consequently, there is a growing need 
to identify so-called new ‘players’ implicated in this 
process. Lemur tyrosine kinase 3 (LMTK3), a member 
of the receptor tyrosine kinase (RTK) family, has been 
previously identified as a central protein involved in 
breast cancer growth and endocrine resistance and it has 
also been subjected to Darwinian positive selection as 
described [2-5]. Moreover, increased LMTK3 expression 
associates with poor overall and disease-free survival, 
indicative of a potential involvement of LMTK3 in breast 
cancer progression.
Cell migration and invasion are the early steps 
of the metastatic process controlled by cellular signals 
that stimulate changes in cell adhesion and cytoskeleton 
formation [6]. We have now reported that LMTK3 is 
highly expressed in triple negative breast cancers and 
it is implicated in actin cytoskeleton remodeling, focal 
adhesion formation and increased cell motility [7]. In 
vitro experiments showed that overexpression of LMTK3 
accelerates the dispersion and invasion of breast cancer 
cells towards the matrigel and collagen, while it increases 
actin protrusions and focal adhesion formations on the edge 
of migrating cells. To address the underlying molecular 
mechanisms, a stable isotope labeling by amino acids 
in cell culture (SILAC)-based proteomics analysis was 
implemented to investigate the downstream components 
of LMTK3-regulated cascade. Interestingly, integrin 
subunits α5 (ITGA5) and β1 (ITGB1), central receptors 
in metastatic signal relay, were positively regulated by 
LMTK3, while high LMTK3 levels were also correlated 
with increased ITGB1 expression in breast cancer patient 
samples. In support of the role of LMTK3 in metastatic 
progression, a proof-of-concept in vivo metastatic mouse 
model was generated, after injecting parental T47D breast 
cancer cells and T47D cells overexpressing LMTK3 into 
the mammary fat pads of female NOD/SCID mice. Our 
preliminary results revealed that only the T47D-LMTK3 
mice developed metastasis in the mammary fat pad 
after 7 weeks, suggesting the contribution of LMTK3 in 
metastatic potential (unpublished data).
Similar to other RTKs, LMTK3 can directly interact 
with the adaptor protein GRB2, activate RAS-GTPase 
family members subsequently leading to upregulated 
serum response factor (SRF) activity, resulting in increased 
ITGA5 and ITGB1 gene transcription. A set of gain- and 
loss-of-function experiments showed that LMTK3 could 
stimulate SRF indirectly through its action on cell division 
control protein 42 homolog (CDC42). However, other 
alternative mechanisms merit investigation, including the 
possibility that LMTK3 might activate SRF through direct 
phosphorylation. In support of this hypothesis, in silico 
analysis revealed potential phosphorylation sites of SRF 
targeted by LMTK3 that are currently under examination. 
Moreover, the topology of LMTK3 (cytoplasmic, nuclear 
and to a lesser degree in the cell membrane), implies that 
LMTK3 may be capable of shuttling between subcellular 
compartments upon specific stimuli (i.e. posttranslational 
modifications) and other cellular conditions. Therefore, 
Fig 1: Proposed model of LMTK3 action in cancer 
metastasis. In response to various stimuli (i.e ligands binding, 
regulation by kinases or phosphatases, etc) LMTK3 activates 
Ras-GTPase family through GRB2, enhancing the activity of 
the SRF transcription factor. In parallel, LMTK3 might activate 
SRF through direct phosphorylation that eventually results in the 
activation of integrins transcription, which subsequently leads to 
increased cancer cell invasion and metastasis. 
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understanding the exact role(s) of LMTK3 in different 
cellular compartments is imperative. In order to 
characterize substrates phosphorylated by LMTK3, a 
high-throughput in vitro kinase assay screen is in progress 
that will further help us uncover the signaling pathways 
that LMTK3 is implicated in and decipher its contribution 
in disease.
Furthermore, elucidating the upstream mechanisms 
of LMTK3-regulation is also essential. Till now, there 
have been no studies regarding the existence of any 
LMTK3-specific ligand(s) or other proteins (i.e. kinases, 
phosphatases, etc.) that can directly activate/inactivate the 
catalytic activity of LMTK3. Unraveling the upstream 
signaling and cross-talk pathways of LMTK3 would 
greatly improve our understanding of the underlying 
mechanisms that contribute to the regulation of LMTK3 
and its involvement in invasion and metastasis (Fig 1). 
In aggregate, based on our results so far, LMTK3 
appears to be a promising new target against breast cancer 
progression and metastasis. Additional work is required to 
broaden our knowledge of LMTK3 functions at molecular 
and cellular levels. In parallel, a drug screening program 
will facilitate the identification of specific LMTK3 
inhibitors, which could eventually aid to tackle breast 
cancer metastasis and endocrine resistance. 
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